Chemotherapy for advanced adrenal cancer: Improvement from a molecular approach?

BJU International

Volumn 108, Issue 10, 2011, Pages 1546-1554

  Costa, Renata ^a   Wesolowski, Robert ^a   Raghavan, Derek ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b LEVINE CANCER INSTITUTE   (United States)

Author keywords

adrenal carcinoma; chemotherapy; cisplatin; gene; mitotane; targeted therapies

Indexed keywords

B RAF KINASE; BETA CATENIN; BEVACIZUMAB; CAPECITABINE; CISPLATIN; CIXUTUMUMAB; CYCLOPHOSPHAMIDE; DNA VACCINE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ETOPOSIDE; FIGITUMUMAB; FLUOROURACIL; GEFITINIB; GEMCITABINE; GLYCOPROTEIN P; GOSSYPOL; IRINOTECAN; K RAS PROTEIN; MITOTANE; PACLITAXEL; RAF PROTEIN; SORAFENIB; STREPTOZOCIN; SURAMIN; TENIPOSIDE; UNINDEXED DRUG; VINCRISTINE; WNT PROTEIN;

ADRENAL CORTEX CARCINOMA; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER REGRESSION; CANCER SURVIVAL; DNA IMMUNIZATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION REGULATION; GENE MUTATION; HUMAN; HYPERURICEMIA; LEUKOPENIA; LIVER FUNCTION TEST; METASTASIS; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROLOGIC DISEASE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEINURIA; REVIEW; SEPTIC SHOCK; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; SYSTEMIC THERAPY; UNSPECIFIED SIDE EFFECT;

ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FORECASTING; HUMANS; MITOTANE; MOLECULAR TARGETED THERAPY; SURAMIN;

EID: 80255129384     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10464.x     Document Type: Review

References (79)

1. Katz MD, Imperato-McGinley J. Adrenal cancer-endrocinology, diagnosis and clinical staging. In, Raghavan D, Scher HI, Leibel SA, Lange PH, eds, Principles and Practice of Genitourinary Oncology. Philadelphia: Lippincott-Raven, 1997: 981-91
2. Wooten MD, King DK,. Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature. Cancer 1993; 72: 3145-55 (Pubitemid 23356754)
3. Phan AT,. Adrenal cortical carcinoma-review of current knowledge and treatment practices. Hematol Oncol Clin North Am 2007; 21: 489-507; viii-ix (Pubitemid 46844860)
4. Ribeiro RC, Sandrini F, Figueiredo B, et al,. An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proc Natl Acad Sci USA 2001; 98: 9330-5 (Pubitemid 32743916)
5. Michalkiewicz E, Sandrini R, Figueiredo B, et al,. Clinical and outcome characteristics of children with adrenocortical tumors: a report from the International Pediatric Adrenocortical Tumor Registry. J Clin Oncol 2004; 22: 838-45 (Pubitemid 41103595)
6. Roman S,. Adrenocortical carcinoma. Curr Opin Oncol 2006; 18: 36-42 (Pubitemid 43740448)
7. Koschker AC, Fassnacht M, Hahner S, Weismann D, Allolio B,. Adrenocortical carcinoma-improving patient care by establishing new structures. Exp Clin Endocrinol Diabetes 2006; 114: 45-51
8. Weiss LM, Medeiros LJ, Vickery AL Jr,. Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Pathol 1989; 13: 202-6 (Pubitemid 19081702)
9. Kebebew E, Reiff E, Duh QY, Clark OH, McMillan A,. Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World J Surg 2006; 30: 872-8 (Pubitemid 43724119)
10. Norton JA, Le HN,. Adrenal tumors. In, DeVita VT Jr, Hellman S, Rosenberg SA, eds, Principles and Practice of Oncology, 7th edn. Philadelphia: Lippincott, Williams, and Wilkins, 2005: 1534
11. Bilimoria KY, Shen WT, Elaraj D, et al,. Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer 2008; 113: 3130-6
12. Allolio B, Fassnacht M,. Clinical review: adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab 2006; 91: 2027-37 (Pubitemid 43854976)
13. Stojadinovic A, Ghossein RA, Hoos A, et al,. Adrenocortical carcinoma: clinical, morphologic, and molecular characterization. J Clin Oncol 2002; 20: 941-50 (Pubitemid 34141836)
14. Abiven G, Coste J, Groussin L, et al,. Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J Clin Endocrinol Metab 2006; 91: 2650-5 (Pubitemid 44024632)
15. de Reynies A, Assie G, Rickman DS, et al,. Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J Clin Oncol 2009; 27: 1108-15
16. Haq MM, Legha SS, Samaan NA, Bodey GP, Burgess MA,. Cytotoxic chemotherapy in adrenal cortical carcinoma. Cancer Treat Rep 1980; 64: 909-13 (Pubitemid 11139829)
17. Kasperlik-Zaluska AA,. Clinical results of the use of mitotane for adrenocortical carcinoma. Braz J Med Biol Res 2000; 33: 1191-6
18. Bergenstal DM, Hertz R, Lipsett MB, Moy RH,. Chemotherapy of adrenocortical cancer with o,p′-DDD. Ann Intern Med 1960; 53: 672-82
19. Hutter AM Jr, Kayhoe DE,. Adrenal cortical carcinoma. Results of treatment with o,p′DDD in 138 patients. Am J Med 1966; 41: 581-92
20. Lubitz JA, Freeman L, Okun R,. Mitotane use in inoperable adrenal cortical carcinoma. JAMA 1973; 223: 1109-12
21. Macfarlane DA,. Cancer of the adrenal cortex; the natural history, prognosis and treatment in a study of fifty-five cases. Ann R Coll Surg Engl 1958; 23: 155-86
22. Becker D, Schumacher OP,. o,p′DDD therapy in invasive adrenocortical carcinoma. Ann Intern Med 1975; 82: 677-9
23. Dackiw AP, Lee JE, Gagel RF, Evans DB,. Adrenal cortical carcinoma. World J Surg 2001; 25: 914-26 (Pubitemid 32666394)
24. Kirschner LS,. Editorial: paradigms for adrenal cancer: think globally, act locally. J Clin Endocrinol Metab 2006; 91: 4250-2 (Pubitemid 44833393)
25. Dickstein G, Shechner C, Arad E, Best LA, Nativ O,. Is there a role for low doses of mitotane (o,p′-DDD) as adjuvant therapy in adrenocortical carcinoma? J Clin Endocrinol Metab 1998; 83: 3100-3 (Pubitemid 28500941)
26. Haak HR, van Seters AP, Moolenaar AJ, Fleuren GJ,. Expression of P-glycoprotein in relation to clinical manifestation, treatment and prognosis of adrenocortical cancer. Eur J Cancer 1993; 29A: 1036-8 (Pubitemid 23126709)
27. van Slooten H, Moolenaar AJ, van Seters AP, Smeenk D,. The treatment of adrenocortical carcinoma with o,p′-DDD: prognostic implications of serum level monitoring. Eur J Cancer Clin Oncol 1984; 20: 47-53 (Pubitemid 14224356)
28. Kasperlik-Zaluska AA, Cichocki A,. Clinical role of determination of plasma mitotane and its metabolites levels in patients with adrenal cancer: results of a long-term follow-up. J Exp Ther Oncol 2005; 5: 125-32 (Pubitemid 41739372)
29. Haak HR, Hermans J, van de Velde CJ, et al,. Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer 1994; 69: 947-51 (Pubitemid 24140681)
30. Allolio B, Jaursch-Hancke C, Reincke M, Arlt W, Metzler U, Winkelmann W,. Treatment of metastatic adrenal carcinoma with suramin. Dtsch Med Wochenschr 1989; 114: 381-4 (Pubitemid 19086278)
31. La Rocca RV, Stein CA, Danesi R, Jamis-Dow CA, Weiss GH, Myers CE,. Suramin in adrenal cancer: modulation of steroid hormone production, cytotoxicity in vitro, and clinical antitumor effect. J Clin Endocrinol Metab 1990; 71: 497-504
32. Arlt W, Reincke M, Siekmann L, Winkelmann W, Allolio B,. Suramin in adrenocortical cancer: limited efficacy and serious toxicity. Clin Endocrinol (Oxf) 1994; 41: 299-307 (Pubitemid 24278323)
33. Stein CA, LaRocca RV, Thomas R, McAtee N, Myers CE,. Suramin: an anticancer drug with a unique mechanism of action. J Clin Oncol 1989; 7: 499-508 (Pubitemid 19098145)
34. Tso WW,. Gossypol inhibits Ehrlich ascites tumor cell proliferation. Cancer Lett 1984; 24: 257-61 (Pubitemid 15184751)
35. Wu YW, Chik CL, Knazek RA,. An in vitro and in vivo study of antitumor effects of gossypol on human SW-13 adrenocortical carcinoma. Cancer Res 1989; 49: 3754-8 (Pubitemid 19197392)
36. Flack MR, Pyle RG, Mullen NM, et al,. Oral gossypol in the treatment of metastatic adrenal cancer. J Clin Endocrinol Metab 1993; 76: 1019-24 (Pubitemid 23110855)
37. Allolio B, Hahner S, Weismann D, Fassnacht M,. Management of adrenocortical carcinoma. Clin Endocrinol (Oxf) 2004; 60: 273-87 (Pubitemid 38297116)
38. Tattersall MH, Lander H, Bain B, et al,. Cis-platinum treatment of metastatic adrenal carcinoma. Med J Aust 1980; 1: 419-21 (Pubitemid 10002849)
39. Chun HG, Yagoda A, Kemeny N, Watson RC,. Cisplatin for adrenal cortical carcinoma. Cancer Treat Rep 1983; 67: 513-4 (Pubitemid 13106698)
40. Baudin E, Docao C, Gicquel C, et al,. Use of a topoisomerase I inhibitor (irinotecan, CPT-11) in metastatic adrenocortical carcinoma. Ann Oncol 2002; 13: 1806-9 (Pubitemid 35439462)
41. Decker RA, Elson P, Hogan TF, et al,. Eastern Cooperative Oncology Group study 1879: mitotane and adriamycin in patients with advanced adrenocortical carcinoma. Surgery 1991; 110: 1006-13
42. Bates SE, Shieh CY, Mickley LA, et al,. Mitotane enhances cytotoxicity of chemotherapy in cell lines expressing a multidrug resistance gene (mdr-1/P-glycoprotein) which is also expressed by adrenocortical carcinomas. J Clin Endocrinol Metab 1991; 73: 18-29 (Pubitemid 21901094)
43. Bukowski RM, Wolfe M, Levine HS, et al,. Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: a Southwest Oncology Group study. J Clin Oncol 1993; 11: 161-5 (Pubitemid 23059990)
44. Tjalve H, Wilander E, Johansson EB,. Distribution of labelled streptozotocin in mice: uptake and retention in pancreatic islets. J Endocrinol 1976; 69: 455-6
45. Eriksson B, Oberg K, Curstedt T, et al,. Treatment of hormone-producing adrenocortical cancer with o,p'DDD and streptozocin. Cancer 1987; 59: 1398-403 (Pubitemid 17044992)
46. Khan TS, Imam H, Juhlin C, et al,. Streptozocin and o,p'DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use. Ann Oncol 2000; 11: 1281-7
47. Johnson DH, Greco FA,. Treatment of metastatic adrenal cortical carcinoma with cisplatin and etoposide (VP-16). Cancer 1986; 58: 2198-202 (Pubitemid 17170895)
48. Zidan J, Shpendler M, Robinson E,. Treatment of metastatic adrenal cortical carcinoma with etoposide (VP-16) and cisplatin after failure with o,p'DDD. Clinical case reports. Am J Clin Oncol 1996; 19: 229-31
49. Williamson SK, Lew D, Miller GJ, Balcerzak SP, Baker LH, Crawford ED,. Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study. Cancer 2000; 88: 1159-65 (Pubitemid 30127678)
50. Bonacci R, Gigliotti A, Baudin E, et al,. Cytotoxic therapy with etoposide and cisplatin in advanced adrenocortical carcinoma. Br J Cancer 1998; 78: 546-9 (Pubitemid 28360647)
51. Berruti A, Terzolo M, Pia A, Angeli A, Dogliotti L,. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer. Cancer 1998; 83: 2194-200 (Pubitemid 28525402)
52. Berruti A, Terzolo M, Sperone P, et al,. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr Relat Cancer 2005; 12: 657-66 (Pubitemid 41482999)
53. Abraham J, Bakke S, Rutt A, et al,. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist. Cancer 2002; 94: 2333-43 (Pubitemid 34457113)
54. van Slooten H, van Oosterom AT,. CAP (cyclophosphamide, doxorubicin, and cisplatin) regimen in adrenal cortical carcinoma. Cancer Treat Rep 1983; 67: 377-9 (Pubitemid 13054431)
55. Khan TS, Sundin A, Juhlin C, Wilander E, Oberg K, Eriksson B,. Vincristine, cisplatin, teniposide, and cyclophosphamide combination in the treatment of recurrent or metastatic adrenocortical cancer. Med Oncol 2004; 21: 167-77 (Pubitemid 39108007)
56. Hesketh PJ, McCaffrey RP, Finkel HE, Larmon SS, Griffing GT, Melby JC,. Cisplatin-based treatment of adrenocortical carcinoma. Cancer Treat Rep 1987; 71: 222-4 (Pubitemid 17030167)
57. Schlumberger M, Ostronoff M, Bellaiche M, Rougier P, Droz JP, Parmentier C,. 5-Fluorouracil, doxorubicin, and cisplatin regimen in adrenal cortical carcinoma. Cancer 1988; 61: 1492-4 (Pubitemid 18091771)
58. Schlumberger M, Brugieres L, Gicquel C, Travagli JP, Droz JP, Parmentier C,. 5-Fluorouracil, doxorubicin, and cisplatin as treatment for adrenal cortical carcinoma. Cancer 1991; 67: 2997-3000
59. Nakamura M, Miki Y, Akahira J, et al,. An analysis of potential surrogate markers of target-specific therapy in archival materials of adrenocortical carcinoma. Endocr Pathol 2009; 20: 17-23
60. Sasano H, Suzuki T, Shizawa S, Kato K, Nagura H,. Transforming growth factor alpha, epidermal growth factor, and epidermal growth factor receptor expression in normal and diseased human adrenal cortex by immunohistochemistry and in situ hybridization. Mod Pathol 1994; 7: 741-6
61. Edgren M, Eriksson B, Wilander E, Westlin JE, Nilsson S, Oberg K,. Biological characteristics of adrenocortical carcinoma: a study of p53, IGF, EGF-r, Ki-67 and PCNA in 17 adrenocortical carcinomas. Anticancer Res 1997; 17: 1303-9 (Pubitemid 27182456)
62. Kamio T, Shigematsu K, Sou H, Kawai K, Tsuchiyama H,. Immunohistochemical expression of epidermal growth factor receptors in human adrenocortical carcinoma. Hum Pathol 1990; 21: 277-82 (Pubitemid 20081227)
63. Quinkler M, Hahner S, Wortmann S, et al,. Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine. J Clin Endocrinol Metab 2008; 93: 2057-62 (Pubitemid 351831515)
64. Wortmann S, Quinkler M, Ritter C, et al,. Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma. Eur J Endocrinol 2010; 162: 349-56
65. Libe R, Fratticci A, Bertherat J,. Adrenocortical cancer: pathophysiology and clinical management. Endocr Relat Cancer 2007; 14: 13-28 (Pubitemid 47521719)
66. Almeida MQ, Fragoso MC, Lotfi CF, et al,. Expression of insulin-like growth factor-II and its receptor in pediatric and adult adrenocortical tumors. J Clin Endocrinol Metab 2008; 93: 3524-31
67. Haluska P, Worden F, Olmos D, et al,. Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemother Pharmacol 2010; 65: 765-73
68. Chuman Y, Zhan Z, Fojo T,. Construction of gene therapy vectors targeting adrenocortical cells: enhancement of activity and specificity with agents modulating the cyclic adenosine 3′,5′-monophosphate pathway. J Clin Endocrinol Metab 2000; 85: 253-62 (Pubitemid 32268823)
69. Kirschner LS,. Emerging treatment strategies for adrenocortical carcinoma: a new hope. J Clin Endocrinol Metab 2006; 91: 14-21 (Pubitemid 43069108)
70. Schott M, Reincke M, Ortmann D, Bornstein SR,. Immunotherapy: new strategies for the treatment of adrenocortical carcinoma. Horm Metab Res 2003; 35: 451-3 (Pubitemid 37378275)
71. Montoya M, Brown JW, Fishman LM,. Comparative effects of chemotherapeutic agents on the growth and survival of human adrenal carcinoma cells in culture. Horm Metab Res 2008; 40: 302-5 (Pubitemid 351859439)
72. Juliano RL, Ling V,. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976; 455: 152-62
73. Bradley G, Juranka PF, Ling V,. Mechanism of multidrug resistance. Biochim Biophys Acta 1988; 948: 87-128
74. Flynn SD, Murren JR, Kirby WM, Honig J, Kan L, Kinder BK,. P-glycoprotein expression and multidrug resistance in adrenocortical carcinoma. Surgery 1992; 112: 981-6 (Pubitemid 23008222)
75. Schteingart DE, Benitez R, Bradford C, Narayan A, Wang S,. Expression of anti-apoptosis genes determines the response of adrenal cancer to apoptosis-inducing chemotherapy. Anticancer Res 2010; 30: 4805-9
76. Malandrino P, Al Ghuzlan A, Castaing M, et al,. Prognostic markers of survival after combined mitotane- and platinum- chemotherapy in metastatic adrenocortical carcinoma. Endocr Related Cancers 2010; 17: 797-807
77. Berthon A, Sahut-Barnola I, Lambert-Langlais S, et al,. Constitutive beta-catenin activation induces adrenal hyperplasia and promotes adrenal cancer development. Hum Mol Genet 2010; 19: 1561-76
78. El Wakil A, Lalli E,. The Wnt/beta catenin pathway in adrenocortical development and cancer. Molec Cell Endocrinol 2011; 332: 32-7
79. Kotoula V, Sozopoulos E, Litsiou H, et al,. Mutational analysis of the BRAF, RAS and EGFR genes in human adrenocortical carcinomas. Endocr Related Cancers 2009; 16: 565-72